Vienna-based f-star Biotechnology's platform allows it to enhance the functionality of antibodies by introducing additional binding sites. F-star is also investigating antibody fragments and what it calls "compressed" antibodies, or protein scaffolds with key antibody characteristics tacked on, but much smaller in size. These, it claims, may be easier to produce than full-sized antibodies, with better tissue penetration and potentially better efficacy.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
Dr Reddy’s CEO discusses the growth opportunity for semaglutide, including production capacity and ‘crazy’ demand indications, and a potential 20-plus product GLP-1 portfolio. All eyes are also on an upcoming hearing in India pertaining to Novo Nordisk’s semaglutide patent in the country.
Deal Snapshot: The addition of Hengrui's HRS-9821, a China-originated fast-follower of Verona’s Ohtuvayre in chronic obstructive pulmonary disease, should enable GSK’s COPD therapy portfolio to stack up well against increasing competitors in the indication, including biologics and small molecules.
In this week's episode: Sanofi’s Vicebio buy; Sarepta halts US Elevidys shipments; Novartis warning over Europe; US CRL for Genentech’s Columvi; and an interview with Novavax.